Correlation Between Inflammatory Molecular Markers And Vascular Cognitive Impairment In Patients With Ischemic Cerebral Small Vessel Disease

Objectives Levels of Matrix Metalloproteinases 9(MMP-9),Phospholipase A2(Lp-PL-A2),Monocyte Chemotactic Protein-1(MCP-1)and Pentamerin 3(PTX3)were detected in patients with ischemic cerebral small vessel disease(CSVD).To explore the correlation between plasma inflammatory molecular markers and vascular cognitive impairment in ischemic CSVD patients,so as to provide evidence for early clinical intervention of cognitive impairment in ischemic CSVD patients.Methods 300 patients with ischemic CSVD who were hospitalized in the Department of Neurology,North China University of Science and Technology from October 2018 to December 2019 were selected as subjects for the study.Cognitive function was assessed by Mini Mental State Examination(MMSE).According to the score results,patients with ischemic CSVD were divided into normal cognitive group(n=106)and cognitive impairment group(n=194),among which the cognitive impairment group were further divided into mild cognitive impairment group(n=100),moderate cognitive impairment group(n=60)and severe cognitive impairment group(n=34).Another 60 cases of healthy subjects in the same period were selected as a normal control group.The levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 were detected by double-antibody sandwich method,and the correlation between vascular cognitive impairment and plasma inflammatory molecular markers in ischemic CSVD patients was analyzed and compared.Results 1 Compared with normal control group,the levels of FPG,TC,HCY,UA were increased in cognitive normal group and cognitive impairment group of the ischemic CSVD patients,and the levels of FPG,TC,HCY,UA in cognitive impairment group were significantly higher in cognitive normal group(P<0.05).2 The levels of MMP-9(709.92±201.91μg/L and 1083.71±470.52μg/L vs 553.57±167.14μg/L),Lp-PL-A2(35.46±8.15μg/L and 58.60±47.09μg/L vs 24.32±2.91μg/L),MCP-1(202.47±70.59μg/L and 279.42±84.14μg/L vs 157.90±86.07μg/L),PTX3(8.66±3.85μg/L and 14.02±8.43μg/L vs 7.35±2.83μg/L)were significantly higher in cognitive impairment group and cognitive normal group than normal control group(P<0.05).Compared with cognitive normal group,the levels of MMP-9,Lp-PL-A2,MCP-1,PTX3 were increased in cognitive impairment group,the difference was statistically significant(P<0.05).By taking MMP-9,Lp-PL-A2,MCP-1,PTX3 greater than or equal to the mean as exposure,to analyze the correlation between vascular cognitive impairment and plasma inflammatory factors in ischemic CSVD patients.The results showed that the levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 in ischemic CSVD patients were associated with vascular cognitive impairment(P<0.05).3 Multivariate logistic regression analysis showed that the levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 were still associated with vascular cognitive impairment in ischemic CSVD patients after controlling for other factors(OR=3.801,95%CI=1.904-7.588,P<0.05;OR=3.722,95%CI=1.610-8.604,P<0.05;OR=3.096,95%CI=1.557-6.155,P<0.05;OR=2.514,95%CI=1.229-5.144,P<0.05).4 Compared with mild cognitive impairment group,the levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 in moderate and severe cognitive impairment group were increased,and the differences were statistically significant(P<0.05).The levels of MMP-9,Lp-PL-A2,MCP-1,PTX3 in severe cognitive impairment group was significantly higher than in moderate cognitive impairment group(P<0.05).5 The levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 were negatively correlated with MMSE scores in ischemic CSVD patients(r=-0.709,P<0.05;r=-0.583,P<0.05;r=-0.554,P<0.05;r=-0.508,P<0.05).6 Multiple linear regression analysis showed that the levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 in ischemic CSVD patients were influencing factors of the severity of vascular cognitive impairment(P<0.05).Conclusions 1 Plasma MMP-9,Lp-PL-A2,MCP-1 and PTX3 are related to vascular cognitive impairment in patients with ischemic cerebral small vessel disease.2 The levels of MMP-9,Lp-PL-A2,MCP-1 and PTX3 increased,and the degree of vascular cognitive impairment aggravated in ischemic cerebral small vessel disease patients.Figure0;Table9;Reference 183...